Abstract 15047: Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients With Heart Failure

BackGround: Cyclophilin A (CyPA) is secreted from cardiac fibroblasts in response to angiotensin II or mechanical stretch and promotes cardiac hypertrophy, fibrosis and the development of arteriosclerosis. We have recently demonstrated that CyPA is a novel biomarker for severity of coronary artery disease (CAD) and for predicting adverse prognosis in patients with CAD. However, the role of CyPA as a biomarker for patients with heart failure (HF) remains to be elucidated. Methods and Results: In 175 consecutive patients who were hospitalized in Tohoku University Hospital for HF, we measured plasma levels of CyPA and BNP. Additionally, we examined their prognostic impacts during the follow-up (median 5.8 years). Plasma CyPA levels were significantly elevated in HF patients (15.1±9.8 ng/mL, n=175) than in healthy controls (3.3±2.2 ng/mL, n=10, Pu003c0.001). Similarly, plasma BNP levels were significantly elevated in HF patients (378.8±655.8 pg/mL, n=175) than in healthy controls (22.6±20.4 pg/mL, n=10, Pu003c0.001)....